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Abstract: 
Atrial fibrillation (AF) is a frequent chronic dysrythmia with an incidence that increases with age (>40). Because of its 
medical and socio-economic impacts it is expected to become an increasing burden on most health care systems. AF is a 
multi-factorial disease for which the identification of subtypes is warranted. Novel approaches based on the broad concepts 
of systems biology may overcome the blurred notion of normal and pathological phenotype, which is inherent to high 
throughput molecular arrays analysis. Here we apply an internal contrast algorithm on AF patient data with an analytical 
focus on potential entry pathways into the disease. We used a RMA (Robust Multichip Average) normalized Affymetrix 
micro-array data set from 10 AF patients (geo_accession #GSE2240). Four series of probes were selected based on 
physiopathogenic links with AF entryways: apoptosis (remodeling), MAP kinase (cell remodeling), OXPHOS (ability to 
sustain hemodynamic workload) and glycolysis (ischemia). Annotated probe lists were polled with Bioconductor packages 
in R (version 2.7.1). Genetic profile contrasts were analysed with hierarchical clustering and principal component analysis. 
The analysis revealed distinct patient groups for all probe sets. A substantial part (54% till 67%) of the variance is explained 
in the first 2 principal components. Genes in PC1/2 with high discriminatory value were selected and analyzed in detail. We 
aim for reliable molecular stratification of AF. We show that stratification is possible based on physiologically relevant gene 
sets. Genes with high contrast value are likely to give pathophysiological insight into permanent AF subtypes. 
 
Keywords: atrial fibrillation; gene expression; Robust Multichip Average; genetic profile 
 
Background: 
Atrial fibrillation (AF) is a frequent chronic dysrythmia 
with an incidence that increases with age (>40) [1]. Due to 
its medical and socio-economic impacts and, of the aging 
European/ Western /Japanese populations, it is projected to 
become an increasing burden on most health care systems 
[2]. Besides the obvious medical emergencies, the costs 
include the chronic corrective therapies (pacemakers, 
surgical ablations, etc.), the severe complications 
(thromboembolisms, strokes e.a., [3]) and various other 
hospitalisation costs. Atrial fibrillation is a multi-factorial 
disease for which the identification of subtypes - molecular 
categories - will be both useful and needed to provide 
better and cost-effective therapies [4] and to improve the 
quality of future clinical studies.   
 
With the advent of high-throughput molecular analyses, the 
classical paradigm of a failing gene corresponding to an 
altered/pathological phenotype is being lost. It is widely 
accepted that an altered genotype can lead to a healthy 
phenotype via numerous compensation mechanisms, but it 
is becoming also apparent - and much less known - that 
even healthy genotypes could lead to 
defective/pathological phenotypes. Indeed a given cell 
phenotype could be considered as a state more akin to the 
orbit of a chaotic strange attractor than a definitive frozen 
combination of gene expression [5]. There seem to exist 
many ways to dissociate genotypes from phenotypes [6], 
hence the conceptual impossibility of a bona fide control 
group. In this context of a blur between the notions of 
normal and pathological phenotypes, novel analytical 
approaches are warranted based on the broad concepts of 
system biology [7].  
 
To provide evidence of robust/reliable stratification based 
on molecular profiles is one of the biggest challenges in 
molecular medicine. Exploratory tools from multivariate 
statistics and data mining offer solutions, but often miss a 
biological and physiological focus, and neglect the 
dynamic reality of the biological system. As part of a series 
of feasibility studies, we are using an internal contrast 
analysis - i.e without comparison with a control population 
- of an existing micro-array data-set from chronic AF 
patients  [8] in which up-regulation of metabolism was 
found to be a key marker. Prior to their chronic stage Bioinformation by Biomedical Informatics Publishing Group                            open access 
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where tissue remodelling acts as a positive feedback for the 
phenotype, AF patients enter this pathology either via 
ischemia-related, work-load and hypertension, and/or 
degenerative problems, each of which can be potentially 
traced at a molecular level.  
 
Methodology: 
Datasets 
We used the RMA (Robust Multichip Average, [9]) 
normalized gene expression micro-array data set for 4 
series of probes linked to either apoptosis, glycolysis, 
OXPHOS and MAP kinase pathway. Those probe sets 
were selected because of their potential physiopathogenic 
links with the entryways toward AF: apoptosis 
(remodeling), MAP kinase (cell and tissular 
differentiation), OXPHOS (ability to sustain workload 
including high tensions), glycolysis (ischemic or pre-
ischemic situations). The data were obtained from 10 
patient samples in an Affymetrix -set (geo_accession 
#GSE2240). 
 
Gene selection 
Bioconductor, version 2.2 [10] and R, version 2.7.1 
(packages: hgu133b, KEGG, annotate, cluster) provided 
the tools to select functional category-related genes that are 
prevalent in the KEGG database (function 
hgu133bPATH2PROBE).  
 
Contrast analysis  
Overall similarity in genetic profiles between patients was 
apparent from the dendrograms after hierarchical clustering 
(HC) [11] based on the “dissimilarity’ correlation matrix. 
To select genes with high contrast value between all 
patients a principal component analysis (PCA) [12] was 
done. Gene probes were selected based on the loadings 
vector of the first and second principal component. 
Selected genes were further classified according to 
absolute univariate expression levels. We found contrast 
mostly interpretable for genes with (i.) low variance in 
between-probe (ii.) high difference between patient groups 
and (iii.) high deviation from the over-all median patient 
value for a given gene. 
 
Discussion: 
Micro-array analysis is a high-throughput technique, which 
allows probing the expression levels of thousands of genes 
simultaneously. Though at first sight arrays provide a 
powerful tool, conclusions and robustness of the technique 
are still heavily debated and solutions are presented to 
address standardization of experimental conditions, 
calculation of proper sample size, pre-processing of data 
and statistical inference of gene signals, to name a few. 
Systems biology provides a useful framework, mainly 
addressing the “dynamics” and the concepts of normality, 
and of modularity in biological networks. In supra-
ventricular arrhythmia, time-dependent changes for 
functional groups of genes were recently investigated in 
canine models [13].  
 
Barth and colleagues found that atrial tissue acquires 
ventricular characteristics, up-regulation of metabolic 
genes was also apparent in chronic AF patients. The multi-
factorial pathophysiological patterns may come more 
apparent from a patient-centric viewpoint. Therefore we 
applied contrast analysis within the AF patient group, 
aiming at finding the genes for which divergence were 
maximal, and which contributed the most to the variations 
in the expression signals.  
 
In Figure 1, HC and PCA of AF patients based on the 
apoptotic gene set is illustrated. Based on gene expression 
profiles, multivariate analysis (HC and PCA) of patients 
revealed distinct clustering patterns of the patients in all 4 
datasets. The most striking observation is the consistent 
grouping of 3 patients (patient id: 1, 2, 3) for the 4 datasets, 
clearly separated from the rest, and the isolation of one 
patient (patient id: 10), bearing little resemblance to all of 
the other AF patients. The analysis also revealed high 
similarity of another group (id: 5, 6, 9) in all datasets.  
 
For all datasets a substantial proportion of the variance 
(54% till 67%) in the dataset is captured in the first 2 
principal components (cumulative proportion for 
apoptosis: 0.53 0.67, oxphos: 0.51 0.63, glycolysis: 0.31 
0.54, MAPK: 0.42 0.67). Gene probes with high 
discriminatory value were selected based on high loadings 
in PC1/2, either positive (+) or negative (-) (see Table 1 in 
supplementary material). These probes are likely to be the 
most relevant in terms of the between-patient contrast. It 
should be noted that genes are often mapped to multiple 
probesets. Affymetrix arrays such as the hgu133b are 
designed to target the 600 bp at the 3' end of the transcript, 
not the start of the transcript. Therefore many-to-one 
mappings between probesets and genes are often due to 
alternative splicing, use of alternative poly (A) sites, or 
annotation errors [14, 15]. This could add to the variations, 
a point we will discuss later. 
 
We are especially interested in genes for which the 
expression range for all probes (i.e. with identical 
annotation), clearly differs among patients, and thus 
provide unambiguous discrimination between those 
patients. To identify such genes, we also explored the 
univariate expression levels of all probes. Doing so, we 
could identify 3 types of genes. The genes for which all 
probe levels were markedly different between patients and 
displayed nearly no variance within a single patient, those 
were defined as Class I, and are reliable signals. The genes, 
for which the intra-patient variance of the expression levels 
between their various probes was large, were identified as 
Class II. For those, the high contrast was more likely due 
to the spread response instead of bona fide differences in 
expression levels; hence these are not correct signals. Then 
we also identified genes for which both a marked 
difference in levels between different patients could be 
recorded, and at the same time a large intra-patient 
variance for the response of gene expression for the 
various probes, those were termed Class III and could be 
considered acceptable signals. Hence we evidence that we 
could identify and classify 36 different genes, which are 
reliable markers and could be used to categorize the 
patients. The split per pathological entryway was: for 
MAPK (8 class I, 0 class II, 3 class III), for glycolysis (7, 
0, 4), for OXPHOS (7,1,1) and for apoptosis (4, 2, 2).   
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Figure 1: Analysis of apoptosis gene set. HC (a) of AF patients shows 2 distinct clusters of patients. PCA analysis (b) 
corroborates clear differentiation of patient AF1-2-3 (dashed group). Inset: example of univariate expression levels within 
patients of CFLAR (CASP8 and FADD-like apoptosis regulator), a gene with highest loadings on PC1. 
 
The Class II – i.e. the non-reliable and/or irrelevant 
markers – were GAPDH (glucose phosphate 
dehydrogenase), Acetyl-coA synthase 1 (whereas Acetyl-
coA synthase 2 fell into class I), ADHFE (alcohol 
dehydrogenase), ENOβ3 (muscular isoform of β enolase), 
PPP3R (protein phosphatase 3 regulatory subunit α), CYC 
(cytochrome C). Surprisingly these are all metabolic 
markers.  
 
A closer look at Class I markers reveals interesting facts 
(Figure 1, PCA lower inset for an example). For instance, 
in 3 patients (id:1,2,3), MAP3K16 levels - an apoptotic 
effector involved in the re-organization of actin filaments 
[16] - are up-regulated and, this occurs in parallel with the 
marked up-regulation of the SOS1 gene - a well known 
guanine nucleotide exchange protein which links mitogen- 
activated kinase and cytoskeletal elements like actin. 
Hence these patients differ from all the others in that they 
are re-modelling their heart tissue. In those 3 patients, 
PPP3CA (the catalytic subunit of protein phosphatase A), 
(NDUFFS8) NADH-coQ reductase, and ubiquinol-
cytochrome C reductase core protein II (UQCRC2) are also 
up-regulated. Those would reflect an enhanced electron 
transport chain activity. It is worth noticing that 
dehydrolipoamide dehydrogenase (DLD), a flavoprotein 
linked to electron transport and the Krebs cycle is also up-
regulated. It could thus be concluded that these 3 patients 
are markedly different from a metabolic standpoint. The 
CFLAR (caspase 8 FADD-like apoptosis regulator and 
CASP8 (caspase 8 itself) are respectively up- and down 
regulated. CFLAR is transducing external triggering of 
apoptosis; this is coupled with the fact that effector 
caspases are not up-regulated and the fact that XIAP - a 
post-mitochondrial inhibitor of apoptosis - is normal. In 
contrast within 3 other patients (id: 5,6,8), XIAP is down-
regulated, those latter patients are hence more apoptotic 
and less remodelling than the 3 former ones. The patients 
(id: 4, 5, 6) had marked increases in FG18 - a fibroblast 
growth factor isoform, important for cell proliferation and 
inflammation, and whose overexpression can lead to 
abnormalities - whereas patients (id: 1,2,3) had decreases. 
Once more, this is consistent with those 2 groups of 
patients being functionally very different. Another and 
potentially important marker distinguishing those two 
groups is the AKT3 gene, a protein kinase B isoform with 
some oncogenic activity but selectively expressed in the 
heart [17]. It promotes cell growth and is known to have 
some cardioprotective effect during re-modelling, but a 
continuous overexpression would lead to dysfunctional 
maladaptive hypertrophy. Patients (id: 1, 2, 3) are up-
regulated whereas patients (id:4, 5, 6) are down-regulated. 
The first group is hence cardio-protected vs. the second, 
but could also become more dysfunctional on the long 
term. At any rate AKT3 is likely to be an important follow-
up marker. Two isoforms of aldolase (ALDOA and 
ALDOB, a glycolytic enzyme) showed an interesting 
pattern: all patients who were up for ALDOA were down 
for ALDOB and conversely, with the exception of 2 of the 
10 patients (id: 1, 5). Noteworthy patient 10 was markedly 
different from all the other for most of the 36 markers we 
studied. 
 
Conclusion: 
We aim for a reliable patient stratification based on 
molecular profiles without the use of a “normal” group. 
We showed that by contrast analysis; we could identify 
patient clusters and individual markers. By using objective 
criteria, those markers could be further appraised for their 
biological reliability. Even with a small cohort (10 AF 
patients in total), we could identify at least 2 markedly 
different sub-populations, which differed based on 
potential entryway into the disease. One group (id: 1,2,3) 
differs metabolically and functionally from another. While 
both groups have some apoptotic markers, their molecular 
context is highly different as the first had more MAP-
kinase activation (hypertrophy) and effector caspases were 
less controlled in the second. We could also identify an 
interesting prognostic follow-up marker. However we have Bioinformation by Biomedical Informatics Publishing Group                            open access 
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to highlight several caveats. There is a high variance 
between probes for one gene and hence quality control is 
warranted. This variance can arise from actual differences 
(alternate splices,…), problems on the DNA CHIP or in 
annotation. In our feasibility study, we face clear 
limitations, e.g. the number of patients is small and not all 
apoptosis genes are included (e.g. no VDAC’s). However 
we showed that stratification is possible based on 
physiologically relevant gene sets. Genes with high 
contrast value in PCA are likely to give pathophysiological 
insight into “permanent” AF subtypes. It is our interest to 
extend this exploratory analysis with classification 
approaches using independent training and validation data 
sets. In a future programme we also like to contrast 
dynamic changes in expression patterns with a focus on AF 
entry point-related molecular signatures in a reductionist 
animal model. 
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Supplementary material 
 
Table 1: Gene probes with highest loadings in principal component (PC) 1 and 2. Genes fall into 4 categories, i.e. 
glycolysis, apoptosis, MAPK and Oxidative Phosphorylation (OXPHOS). Class type in parentheses (I, II, III).  
  Glycolysis  Apoptosis MAPK OXPHOS 
PC1  +: AKR1A (I), BPGM, 
ALDH1A, ALDOB (I) 
 
-: GPI (I), ALDOA (I), 
PGK1 (I), GAPDH (II), 
DLD (I), ENO3 (II), 
ADHFE1 
+: CFLAR (I), XIAP 
(I), PRKAR1A,IRAK4  
 
-: CASP8 (I), ATM, 
AKT3 (III), PIK3R (I) 
+ EGFR, FGF18 (I), 
MEF2C 
 
-: ZAK (III), CDC42 
(I), MAP3K2 (III), 
SOS1 (I), PPP3CA (I), 
EGFR, TAOK 
(MAP3K1) (I) 
+ COX4I1 (I), 
NDUFB10 (III), COX7 
(I), NDUFA11 (I) 
 
-: ATP5E 
=: SDHA (II) 
PC2  -: GAPDH (II), 
ALDH1A, DLD (I), 
ACSS2 (I) 
 
+: ACSS1 (II), BPGM, 
ADHFE1 (II) 
+: PPP3R (II), CASP3, 
TNFRSF1A 
 
-: PRKAR1B, 
PRKAR2A (III),CYCS 
(II), XIAP (I), 
PRKAR2A (II) 
+:EGFR, CACNG8 (I), 
PPP3CA (I), MAP3K8, 
SOS1,PPM1A (I) 
 
-:ZAK (III), MRAS, 
FGF12, PLA2G12A (I); 
GRB2 (III) 
+:ATP5F, COX15 (I); 
UQCRC2 (I),NDUFS8 
(I) 
 
-: NDUFV3 (II), 
NDUFA9, NDUFA10, 
COX7B (I), UCRC (I) 
= SDHA (II) 
 